Source Capital Healthcare & Disruptive Growth Conference
February 10 & 11, 2016
New York City
Source Capital Group's 2016 Disruptive Growth & Healthcare Conference, February 10-11, 2016, will feature healthcare companies focusing their operations on unmet medical needs, as well as growth companies with disruptive technologies and business models. The panels will cover disruptive innovations and business models, regenerative medicine, immunotherapy, grant writing, and finally a discussion regarding NOLs and rights offerings. The audience is more than 400 institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers, source representatives and their clients – all of whom recognize the tremendous opportunities of disruptive ideas and their infinite potential at market introduction. For more information visit www.SourceGRP.com
Abeona Therapeutics, Inc. (ABEO)
Abeona Therapeutics, Inc. (NASDAQ: ABEO) develops and delivers gene therapy and plasma-based products for severe and life-threatening diseases. The company's lead programs are ABO-101 and ABO-102, which are adeno-associated virus-based gene therapies for the treatment of Sanfilippo syndrome. Abeona expects to commence clinical trials for these programs later this year. Additionally, the company is developing ABO-201 gene therapy for the treatment of juvenile Batten disease and ABO-301 for the treatment of Fanconi anemia disorder using a novel gene editing method. For more information, visit the company's website at www.abeonatherapeutics.com.
Aethlon Medical, Inc. (AEMD)
Aethlon Medical, Inc. (NASDAQ: AEMD) is a leading developer of affinity biofiltration devices to treat life-threatening diseases. The company's lead therapeutic candidate, Aethlon Hemopurifier®, is a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory systems of treated individuals. Hemopurifier therapy is currently being advanced under an FDA-approved clinical study. Additionally, Aethlon provides government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. For more information, visit the company's website at www.aethlonmedical.com.
Akers Biosciences, Inc. (AKER)
Akers Biosciences, Inc. (NASDAQ: AKER) was founded in 1989 with the objective of developing proprietary, in vitro diagnostic technologies that accelerate the rate at which clinicians, and in some cases consumers, can obtain health information. The tests and sample preparation devices that emerge from the company's rapid technology platforms are designed to provide the same level of accuracy as traditional laboratory testing methods, but at a fraction of the cost and turn-around time. Akers Biosciences is dedicated to the development of time- and cost-efficient, single-use devices that can be utilized almost anytime, anywhere. For more information, visit the company's website at www.akersbio.com.
Amedica Corp. (AMDA)
Amedica Corp. (NASDAQ: AMDA) develops Silicon Nitride orthopedic and spinal implants. It is the only company that has FDA approval to produce and distribute medical grade Silicon Nitride. Amedica's line of Silicone Nitride Interbody Fusion implants are designed to participate in the fusion process, optimizing patient outcomes. Along with spinal fusion implants, Amediac is developing a corrosion-resistant implant components for dental, hip and knee arthroplasty applications. For more information, visit the company's website at www.amedica.com.
Arch Therapeutics, Inc. (ARTH)
Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company developing a novel approach to stop bleeding and control leaking during surgery and trauma care. The company's innovative self-assembling peptide technology platform has been shown to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, the AC5 Surgical Hemostatic Device, is being designed to achieve hemostasis in minimally invasive and open surgical procedures. For more information, visit the company's website at www.archtherapeutics.com.
Aurinia Pharmaceuticals, Inc. (AUPH)
Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) is a late-stage biopharmaceutical company focused on the development of the therapeutic immunomodulating drug candidate voclosporin for the treatment of lupus nephritis. The company leverages its team's past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database to inform and guide its clinical development plans within this therapeutic area. For more information, visit the company's website at www.auriniapharma.com.
Biocept, Inc. (BIOC)
Biocept, Inc. (NASDAQ: BIOC) is developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test known as a liquid biopsy. Biocept has now developed a unique, patented methodology to isolate from the blood rare cells, such as circulating tumor cells as well as cell-free circulating tumor DNA. This will allow the company to provide both FDA-approved and exploratory biomarker analysis without a tissue sample. For more information, visit the company's website at www.biocept.com.
BioTime, Inc. (BTX)
BioTime, Inc. (NYSE BTX) is building a dominant company in the field of regenerative medicine. The company's strategy is to be the leader in the development of pluripotent stem cell-based technologies and to apply those new technologies in the treatment of degenerative diseases that afflict large numbers of people worldwide. BioTime has also advanced other products into human clinical trials during the past year. For more information, visit the company's website at www.biotimeinc.com.
Caladrius Biosciences, Inc. (CLBS)
Caladrius Biosciences, Inc. (NASDAQ: CLBS), through its wholly owned subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. Caladrius works with its clients to overcome the fundamental challenges presented by cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. Around this core expertise, Caladrius strategically develops product candidates, which currently include an innovative therapy for type I diabetes based on a proprietary platform technology for immunomodulation. For more information, visit the company's website at www.caladrius.com.
Cancer Genetics, Inc. (CGIX)
Cancer Genetics, Inc. (NASDAQ: CGIX) is a leader in enabling precision medicine in oncology through the use of oncology biomarkers and molecular testing. CGI has locations in the U.S., India and China, and has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute. The company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the U.S. and have licensure from several states including New York State. For more information, visit the company's website at www.cancergenetics.com.
Cardica, Inc. (CRDC)
Cardica, Inc.'s (NASDAQ: CRDC) technology portfolio is intended to reduce operating time and facilitate minimally invasive and robot-assisted surgeries. Its MicroCutter XCHANGE® 30 includes a cartridge-based articulating surgical stapling device used for transection and resection in multiple open or minimally invasive urologic, thoracic and pediatric surgical procedures, as well as for transection, resection and/or creation of anastomoses in the small and large intestine and the transection of the appendix. The MicroCutter XCHANGE 30 White Cartridge staple has application in vascular tissue. Cardica also manufactures and markets its C-Port®Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery. For more information, visit the company's website at www.cardica.com.
Chembio Diagnostics, Inc. (CEMI)
Chembio Diagnostics, Inc. (NASDAQ: CEMI) is committed to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). At the core of its commitment is its patented Next Generation DPP (Dual Path Platform) technology, a breakthrough in POC diagnostics, offering significant advantages over lateral-flow technologies including: significantly improved sensitivity; multiplexing – multiple test results via a single blood sample (e.g., HIV-Syphilis Assay); and application in a number of indications. For more information, visit the company's website at www.chembio.com.
Cryoport, Inc. (CYRX)
Cryoport, Inc. (NASDAQ: CYRX) provides cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology (IT) and specialized cold chain logistics expertise. The company's leading-edge logistics solutions are designed for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CROs, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. The company's proprietary Cryoport Express® liquid nitrogen dry vapor shippers are validated to maintain a constant below -150°C temperature for a 10-day dynamic shipment duration. Cryoport's Cryoportal™ Logistics Management Platform facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world's largest shipping companies controlling more than 85% of the world's air shipments. For more information, visit the company's website at www.cryoport.com.
Cytori Therapeutics, Inc. (CYTX)
Cytori Therapeutics, Inc. (NASDAQ: CYTX) is committed to providing patients and physicians around the world with medical technologies, which harness the potential of adult stem and regenerative cells from adipose tissue. These technologies enable the research and practice of regenerative medicine in a way that, until now, has not been possible. With the introduction of a family of medical devices, Cytori has made a patient's own clinical grade stem and regenerative cells available to them at the point-of-care. For more information, visit the company's website at www.cytori.com.
CytoSorbents Corp. (CTSO)
CytoSorbents Corp. (NASDAQ: CTSO) is a critical care immunotherapy company using blood purification to treat life-threatening illnesses. The company has developed a new hemoperfusion technology for removing toxins from the blood associated with sepsis, kidney disease, and other conditions. With its flagship product, CytoSorb, approved in the European Union and marketed in 29 countries worldwide, CytoSorbents is committed to helping save the lives and improve the outcomes of critically-ill patients and patient undergoing cardiac surgery around the world. For more information, visit the company's website at www.cytosorbents.com.
Galmed Pharmaceuticals (GLMD)
Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical focused on the development and commercialization of therapeutics for the treatment of liver diseases. The company is developing Aramchol, which is in phase 2b clinical trial for the treatment of non-alcoholic steato-hepatitis in patients who also suffer from obesity and insulin resistance. For more information, visit the company's website at www.galmedpharma.com.
Harvard Apparatus Regenerative Technology (HART)
Harvard Apparatus Regenerative Technology (NASDAQ: HART) makes bioengineered organs for life-threatening conditions. Its technology platform focuses on the function restoration of the airways and esophagus. The company's HART-Trachea technology has been used in several human trachea transplants to date and approved under compassionate use exemptions. However, none of its products are yet approved by a government regulatory authority for marketing. For more information, visit the company's website at www.harvardapparatus.com.
Hemispherx Biopharma, Inc. (HEB)
Hemispherx Biopharma, Inc. (NYSE: HEB) is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx's flagship products include Alferon N Injection and the experimental immunotherapeutics/antivirals Ampligen. Alferon N Injection is the company's injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. For more information, visit the company's website at www.hemispherx.net.
Mast Therapeutics, Inc. (MSTX)
Mast Therapeutics, Inc. (NYSE: MSTX) is leveraging its MAST (Molecular Adhesion and Sealant Technology) platform to develop vepoloxamer (also known as MST-188), its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. The company is also developing AIR001, a sodium nitrite solution for inhalation via nebulization, for the treatment of heart failure with preserved ejection fraction (HFpEF). Vepoloxamer is in a pivotal phase 3 study for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in a phase 2 study for the treatment of patients with chronic heart failure. AIR001 is an investigational new drug being evaluated in two institution-sponsored phase 2a studies in patients with HFpEF. For more information, visit the company's website at www.masttherapeutics.com.
Oasmia Pharmaceutical AB (OASM)
Oasmia Pharmaceutical AB (NASDAQ: OASM) researches, develops and manufactures drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company's approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer. Oasmia is also developing Paclical for the treatment of metastatic breast cancer; Doxophos, a formulation of the cytostatic doxorubicin, for the treatment of breast cancer; Docecal, a patented formulation of cytostatic docetaxel, for the treatment of breast cancer; and OAS-19 to treat various cancers. For more information, visit the company's website at www.oasmia.com.
Oculus Innovative Sciences, Inc. (OCLS)
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) has designed a humanitarian program to respond to unexpected disasters—floods, earthquakes, tsunamis, hurricanes, epidemics and even man-made calamities—by providing product (such as food or medical assistance) to these victims. The product will be available according to the regulatory claims in each area and at the request of emergency first responders and foundations. To this end, Oculus is proactively seeking partnerships with international aid groups that respond to relief needs and improve global health care services. For more information, visit the company's website at www.oculusis.com.
Oncolytics Biotech, Inc. (ONCYF)
Oncolytics Biotech, Inc. (OTC: ONCYF) is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics Biotech's clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN, its proprietary formulation of the human reovirus. Oncolytics Biotech focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use. Its cancer product is a potential therapeutic for tumors possessing an activated Ras pathway. The company was founded in 1998. For more information, visit the company's website at www.oncolyticsbiotech.com.
OncoSec Medical Incorporated (ONCS)
Established in 2011, OncoSec Medical Incorporated (NASDAQ: ONCS) is a San Diego-based biotechnology company pioneering new technologies to stimulate the body's immune system to target and attack cancer. Through its proprietary technology, the company means to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. OncoSec's investigational platform, ImmunoPulse, is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. For more information, visit the company's website at www.oncosec.com.
Opexa Therapeutics, Inc. (OPXA)
Opexa Therapeutics, Inc. (NASDAQ: OPXA) is a biotechnology company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The company's leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy that is in a phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. For more information, visit the company's website at www.opexatherapeutics.com.
Pluristem Therapeutics, Inc. (PSTI)
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) is a clinical-stage biotechnology company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases. Pluristem derives its cell products from human placental cells. These cells are converted into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues. Pluristem's pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. PLX cells require no tissue matching prior to administration, making them an "off-the-shelf" product. For more information, visit the company's website at www.pluristem.com.
Safeguard Scientifics, Inc. (SFE)
Safeguard Scientifics, Inc. (NYSE: SFE) has a distinguished track record of fostering innovation and building market leaders. For six decades, the company has been providing growth capital and operational support to entrepreneurs across an evolving spectrum of industries. Today, Safeguard is focused on two sectors – healthcare and technology. In these sectors, the company specifically targets early- and growth-stage businesses in advertising technology, digital media, financial technology, enterprise software, Internet of Things, devices, diagnostics, digital health and healthcare IT. For more information, visit the company's website at www.safeguard.com.
Soligenix, Inc. (SNGX)
Soligenix, Inc. (OTC: SNGX) is a late-stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, acute radiation enteritis; and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis. For more information, visit the company's website at www.soligenix.com.
StemCells, Inc. (STEM)
StemCells, Inc. (NASDAQ: STEM) is currently engaged in clinical development of its proprietary HuCNS-SC (purified human neural stem cells) platform technology to treat diseases of the human central nervous system (CNS). The company's mission is to address unmet medical needs through the use of novel cell-based therapeutics that hold the promise of better treatments and cures. StemCells is guided by an unwavering commitment to excellence, integrity and innovation as it strives to help improve health and well being worldwide. For more information, visit the company's website at www.stemcellsinc.com.
TapImmune Inc. (TPIV)
TapImmune Inc. (OTCQB: TPIV) is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases. The company's peptide or nucleic acid-based immunotherapeutics comprise one or more naturally processed epitopes designed to comprehensively stimulate patients' T-cells while restoring or further augmenting antigen presentation. TapImmune's technologies are suitable for use as stand-alone medications, as well as in combination with current treatment modalities. For more information, visit the company's website at www.tapimmune.com.
VirtualScopics, Inc. (VSCP)
VirtualScopics, Inc. (NASDAQ: VSCP) is a provider of clinical trial imaging solutions with an unwavering commitment to accelerating drug and medical device development. Medical and scientific expertise, operational flexibility and responsiveness are hallmarks of the company's daily work and collaborative approach. VirtualScopics understands the risks and time constraints that clinical trial study teams, medical directors and imaging scientists face. The company focuses on addressing these challenges by consistently delivering quality imaging data and imaging services on time and within budget. For more information, visit the company's website at www.virtualscopics.com.
Xtant Medical Holdings, Inc. (XTNT)
Bacterin International and X-spine Systems have combined to form Xtant Medical Holdings, Inc. (NYSE: XTNT), a comprehensive supplier of orthopedic and spine surgery products. Pairing the orthobiologics line-up of Bacterin with the hardware suite of X-spine, the union creates an extensive portfolio of highly complementary products that serve the needs of the orthopedic and neurosurgery markets, with minimal overlap. The combined company has an expanded national footprint of over 300 field sales representatives and more than 50 national accounts and regional health systems/IDN contracts, positioning XTANT Medical as a strong competitor in the spine surgery marketplace. For more information, visit the company's website at www.xtantmedical.com.